Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer and Metastasis Reviews
Published in: Cancer and Metastasis Reviews 3-4/2013

01-12-2013 | NON-THEMATIC REVIEW

Personalized radiation therapy and biomarker-driven treatment strategies: a systematic review

Authors: Jean-Emmanuel Bibault, Ingrid Fumagalli, Charles Ferté, Cyrus Chargari, Jean-Charles Soria, Eric Deutsch

Published in: Cancer and Metastasis Reviews | Issue 3-4/2013

Login to get access

Abstract

Radiosensitivity varies to a great extent across tumor types and also between patients bearing the same type of tumor. Radiation oncology pioneered the field of biomarkers with attempts to correlate tumor response to clonogenic survival, tumor potential doubling time (Tpot), and PaO2. Biomarkers predicting the clinical outcome after radiotherapy are already available, but their levels of evidence are heterogeneous. In light of these molecular factors, the issue of personalized radiation therapy in combination or as a standalone modality is addressed. Known molecular prognostic and predictive biomarkers and their present or potential respective therapeutic implications are described for six tumor types where radiotherapy is considered to be part of the mainstay: chemoradiation (e.g., gliomas, head and neck, cervical cancer), radiotherapy with or without androgen deprivation (e.g., prostate), neo-adjuvant chemoradiation (e.g., rectum), or adjuvant radiotherapy (e.g., breast).
Literature
1.
Hayes, D. F., Bast, R. C., Desch, C. E., Fritsche, H., Jr., Kemeny, N. E., Jessup, J. M., et al. (1996). Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. Journal of the National Cancer Institute, 88(20), 1456–1466.PubMed
2.
Hegi, M. E., Diserens, A.-C., Gorlia, T., Hamou, M.-F., De Tribolet, N., Weller, M., et al. (2005). MGMT gene silencing and benefit from temozolomide in glioblastoma. The New England Journal of Medicine, 352(10), 997–1003.PubMed
3.
Rivera, A. L., Pelloski, C. E., Gilbert, M. R., Colman, H., De La Cruz, C., Sulman, E. P., et al. (2010). MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma. Neuro-Oncology, 12(2), 116–121.PubMed
4.
Gerstner, E. R., Yip, S., Wang, D. L., Louis, D. N., Iafrate, A. J., & Batchelor, T. T. (2009). Mgmt methylation is a prognostic biomarker in elderly patients with newly diagnosed glioblastoma. Neurology, 73(18), 1509–1510.PubMed
5.
Brandes, A. A., Franceschi, E., Tosoni, A., Blatt, V., Pession, A., Tallini, G., et al. (2008). MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. Journal of clinical oncology: official journal of the American Society of Clinical Oncology, 26(13), 2192–2197.
6.
Wick, W., Hartmann, C., Engel, C., Stoffels, M., Felsberg, J., Stockhammer, F., et al. (2009). NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. Journal of clinical oncology: official journal of the American Society of Clinical Oncology, 27(35), 5874–5880.
7.
Cairncross, G., & Jenkins, R. (2008). Gliomas with 1p/19q codeletion: a.k.a. oligodendroglioma. Cancer journal (Sudbury, Mass.), 14(6), 352–357.
8.
Bauman, G. S., Ino, Y., Ueki, K., Zlatescu, M. C., Fisher, B. J., Macdonald, D. R., et al. (2000). Allelic loss of chromosome 1p and radiotherapy plus chemotherapy in patients with oligodendrogliomas. International journal of radiation oncology, biology, physics, 48(3), 825–830.PubMed
9.
Cairncross, G., Berkey, B., Shaw, E., Jenkins, R., Scheithauer, B., Brachman, D., et al. (2006). Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. Journal of clinical oncology: official journal of the American Society of Clinical Oncology, 24(18), 2707–2714.
10.
Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., et al. (2009). IDH1 and IDH2 mutations in gliomas. The New England Journal of Medicine, 360(8), 765–773.PubMed
11.
Weller, M., Felsberg, J., Hartmann, C., Berger, H., Steinbach, J. P., Schramm, J., et al. (2009). Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: A prospective translational study of the German Glioma Network. Journal of clinical oncology: official journal of the American Society of Clinical Oncology, 27(34), 5743–5750.
12.
Yip, S., Iafrate, A. J., & Louis, D. N. (2008). Molecular diagnostic testing in malignant gliomas: A practical update on predictive markers. Journal of Neuropathology and Experimental Neurology, 67(1), 1–15.PubMed
13.
Shinojima, N., Tada, K., Shiraishi, S., Kamiryo, T., Kochi, M., Nakamura, H., et al. (2003). Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. Cancer Research, 63(20), 6962–6970.PubMed
14.
Murat, A., Migliavacca, E., Gorlia, T., Lambiv, W. L., Shay, T., Hamou, M.-F., et al. (2008). Stem cell-related “self-renewal” signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma. Journal of clinical oncology: official journal of the American Society of Clinical Oncology, 26(18), 3015–3024.
15.
Brown, P. D., Krishnan, S., Sarkaria, J. N., Wu, W., Jaeckle, K. A., Uhm, J. H., et al. (2008). Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177. Journal of clinical oncology: official journal of the American Society of Clinical Oncology, 26(34), 5603–5609.
16.
Brizel, D. M., Sibley, G. S., Prosnitz, L. R., Scher, R. L., & Dewhirst, M. W. (1997). Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. International journal of radiation oncology, biology, physics, 38(2), 285–289.PubMed
17.
Nordsmark, M., Bentzen, S. M., Rudat, V., Brizel, D., Lartigau, E., Stadler, P., et al. (2005). Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. Radiotherapy and oncology: journal of the European Society for Therapeutic Radiology and Oncology, 77(1), 18–24.
18.
Bussink, J., Kaanders, J. H. A. M., & Van der Kogel, A. J. (2003). Tumor hypoxia at the micro-regional level: Clinical relevance and predictive value of exogenous and endogenous hypoxic cell markers. Radiotherapy and oncology: journal of the European Society for Therapeutic Radiology and Oncology, 67(1), 3–15.
19.
De Schutter, H., Landuyt, W., Verbeken, E., Goethals, L., Hermans, R., & Nuyts, S. (2005). The prognostic value of the hypoxia markers CA IX and GLUT 1 and the cytokines VEGF and IL 6 in head and neck squamous cell carcinoma treated by radiotherapy +/− chemotherapy. BMC Cancer, 5, 42.PubMed
20.
Gee, H. E., Camps, C., Buffa, F. M., Patiar, S., Winter, S. C., Betts, G., et al. (2010). hsa-mir-210 is a marker of tumor hypoxia and a prognostic factor in head and neck cancer. Cancer, 116(9), 2148–2158.PubMed
21.
Calvin, D. P., Hammond, M. E., Pajak, T. F., Trotti, A. M., Meredith, R. F., Rotman, M., et al. (2007). Microvessel density >or=60 does not predict for outcome after radiation treatment for locally advanced head and neck squamous cell carcinoma: results of a correlative study from the Radiation Therapy Oncology Group (RTOG) 90–03 Trial. American Journal of Clinical Oncology, 30(4), 406–419.PubMed
22.
Overgaard, J., Eriksen, J. G., Nordsmark, M., Alsner, J., & Horsman, M. R. (2005). Plasma osteopontin, hypoxia, and response to the hypoxia sensitiser nimorazole in radiotherapy of head and neck cancer: results from the DAHANCA 5 randomised double-blind placebo-controlled trial. The Lancet Oncology, 6(10), 757–764.PubMed
23.
Hoff, C. M., Hansen, H. S., Overgaard, M., Grau, C., Johansen, J., Bentzen, J., et al. (2011). The importance of haemoglobin level and effect of transfusion in HNSCC patients treated with radiotherapy—results from the randomized DAHANCA 5 study. Radiotherapy and oncology: journal of the European Society for Therapeutic Radiology and Oncology, 98(1), 28–33.
24.
Lim, A. M., Rischin, D., Fisher, R., Cao, H., Kwok, K., Truong, D., et al. (2012). Prognostic significance of plasma osteopontin in patients with locoregionally advanced head and neck squamous cell carcinoma treated on TROG 02.02 phase III trial. Clinical cancer research: an official journal of the American Association for Cancer Research, 18(1), 301–307.
25.
Gillison, M. L., D’Souza, G., Westra, W., Sugar, E., Xiao, W., Begum, S., et al. (2008). Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. Journal of the National Cancer Institute, 100(6), 407–420.PubMed
26.
Ang, K. K., Harris, J., Wheeler, R., Weber, R., Rosenthal, D. I., Nguyen-Tân, P. F., et al. (2010). Human papillomavirus and survival of patients with oropharyngeal cancer. The New England Journal of Medicine, 363(1), 24–35.PubMed
27.
Ragin, C. C. R., & Taioli, E. (2007). Survival of squamous cell carcinoma of the head and neck in relation to human papillomavirus infection: Review and meta-analysis. International journal of cancer. Journal international du cancer, 121(8), 1813–1820.PubMed
28.
Lassen, P., Eriksen, J. G., Hamilton-Dutoit, S., Tramm, T., Alsner, J., & Overgaard, J. (2009). Effect of HPV-associated p16INK4A expression on response to radiotherapy and survival in squamous cell carcinoma of the head and neck. Journal of clinical oncology: official journal of the American Society of Clinical Oncology, 27(12), 1992–1998.
29.
Rischin, D., Young, R. J., Fisher, R., Fox, S. B., Le, Q.-T., Peters, L. J., et al. (2010). Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial. Journal of clinical oncology: official journal of the American Society of Clinical Oncology, 28(27), 4142–4148.
30.
Grandis, J. R., & Tweardy, D. J. (1993). Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Research, 53(15), 3579–3584.PubMed
31.
Chung, C. H., Ely, K., McGavran, L., Varella-Garcia, M., Parker, J., Parker, N., et al. (2006). Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas. Journal of clinical oncology: official journal of the American Society of Clinical Oncology, 24(25), 4170–4176.
32.
Maurizi, M., Almadori, G., Ferrandina, G., Distefano, M., Romanini, M. E., Cadoni, G., et al. (1996). Prognostic significance of epidermal growth factor receptor in laryngeal squamous cell carcinoma. British Journal of Cancer, 74(8), 1253–1257.PubMed
33.
Bentzen, S. M., Atasoy, B. M., Daley, F. M., Dische, S., Richman, P. I., Saunders, M. I., et al. (2005). Epidermal growth factor receptor expression in pretreatment biopsies from head and neck squamous cell carcinoma as a predictive factor for a benefit from accelerated radiation therapy in a randomized controlled trial. Journal of clinical oncology: official journal of the American Society of Clinical Oncology, 23(24), 5560–5567.
34.
Ang, K. K., Berkey, B. A., Tu, X., Zhang, H.-Z., Katz, R., Hammond, E. H., et al. (2002). Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Research, 62(24), 7350–7356.PubMed
35.
Bonner, J. A., Harari, P. M., Giralt, J., Azarnia, N., Shin, D. M., Cohen, R. B., et al. (2006). Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. The New England Journal of Medicine, 354(6), 567–578.PubMed
36.
Bonner, J. A., Harari, P. M., Giralt, J., Cohen, R. B., Jones, C. U., Sur, R. K., et al. (2010). Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. The Lancet Oncology, 11(1), 21–28.PubMed
37.
Clarke, M., Collins, R., Darby, S., Davies, C., Elphinstone, P., Evans, E., et al. (2005). Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet, 366(9503), 2087–2106.PubMed
38.
Bartelink, H., Horiot, J.-C., Poortmans, P. M., Struikmans, H., Van den Bogaert, W., Fourquet, A., et al. (2007). Impact of a higher radiation dose on local control and survival in breast-conserving therapy of early breast cancer: 10-year results of the randomized boost versus no boost EORTC 22881–10882 trial. Journal of clinical oncology: official journal of the American Society of Clinical Oncology, 25(22), 3259–3265.
39.
Nguyen, P. L., Taghian, A. G., Katz, M. S., Niemierko, A., Abi Raad, R. F., Boon, W. L., et al. (2008). Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. Journal of clinical oncology: official journal of the American Society of Clinical Oncology, 26(14), 2373–2378.
40.
Voduc, K. D., Cheang, M. C. U., Tyldesley, S., Gelmon, K., Nielsen, T. O., & Kennecke, H. (2010). Breast cancer subtypes and the risk of local and regional relapse. Journal of clinical oncology: official journal of the American Society of Clinical Oncology, 28(10), 1684–1691.
41.
Paulsen, G. H., Strickert, T., Marthinsen, A. B., & Lundgren, S. (1996). Changes in radiation sensitivity and steroid receptor content induced by hormonal agents and ionizing radiation in breast cancer cells in vitro. Acta oncologica (Stockholm, Sweden), 35(8), 1011–1019.
42.
Harris, E. E. R., Christensen, V. J., Hwang, W.-T., Fox, K., & Solin, L. J. (2005). Impact of concurrent versus sequential tamoxifen with radiation therapy in early-stage breast cancer patients undergoing breast conservation treatment. Journal of clinical oncology: official journal of the American Society of Clinical Oncology, 23(1), 11–16.
43.
Pierce, L. J., Hutchins, L. F., Green, S. R., Lew, D. L., Gralow, J. R., Livingston, R. B., et al. (2005). Sequencing of tamoxifen and radiotherapy after breast-conserving surgery in early-stage breast cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology, 23(1), 24–29.
44.
Pietras, R. J., Poen, J. C., Gallardo, D., Wongvipat, P. N., Lee, H. J., & Slamon, D. J. (1999). Monoclonal antibody to HER-2/neureceptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene. Cancer Research, 59(6), 1347–1355.PubMed
45.
Halyard, M. Y., Pisansky, T. M., Dueck, A. C., Suman, V., Pierce, L., Solin, L., et al. (2009). Radiotherapy and adjuvant trastuzumab in operable breast cancer: Tolerability and adverse event data from the NCCTG Phase III Trial N9831. Journal of clinical oncology: official journal of the American Society of Clinical Oncology, 27(16), 2638–2644.
46.
De Azambuja, E., Cardoso, F., De Castro, G., Jr., Colozza, M., Mano, M. S., Durbecq, V., et al. (2007). Ki-67 as prognostic marker in early breast cancer: A meta-analysis of published studies involving 12,155 patients. British Journal of Cancer, 96(10), 1504–1513.PubMed
47.
Elkhuizen, P. H., Voogd, A. C., Van den Broek, L. C., Tan, I. T., Van Houwelingen, H. C., Leer, J. W., et al. (1999). Risk factors for local recurrence after breast-conserving therapy for invasive carcinomas: A case–control study of histological factors and alterations in oncogene expression. International journal of radiation oncology, biology, and physics, 45(1), 73–83.
48.
Pierce, L. J., Levin, A. M., Rebbeck, T. R., Ben-David, M. A., Friedman, E., Solin, L. J., et al. (2006). Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology, 24(16), 2437–2443.
49.
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., et al. (2005). Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature, 434(7035), 917–921.PubMed
50.
Chang, H. Y., Nuyten, D. S. A., Sneddon, J. B., Hastie, T., Tibshirani, R., Sørlie, T., et al. (2005). Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proceedings of the National Academy of Sciences of the United States of America, 102(10), 3738–3743.PubMed
51.
Van de Vijver, M. J., He, Y. D., Van’t Veer, L. J., Dai, H., Hart, A. A. M., Voskuil, D. W., et al. (2002). A gene-expression signature as a predictor of survival in breast cancer. The New England Journal of Medicine, 347(25), 1999–2009.PubMed
52.
Chi, J.-T., Wang, Z., Nuyten, D. S. A., Rodriguez, E. H., Schaner, M. E., Salim, A., et al. (2006). Gene expression programs in response to hypoxia: Cell type specificity and prognostic significance in human cancers. PLoS Medicine, 3(3), e47.PubMed
53.
Nuyten, D. S. A., Kreike, B., Hart, A. A. M., Chi, J.-T. A., Sneddon, J. B., Wessels, L. F. A., et al. (2006). Predicting a local recurrence after breast-conserving therapy by gene expression profiling. Breast cancer research: BCR, 8(5), R62.PubMed
54.
Mamounas, E. P., Tang, G., Fisher, B., Paik, S., Shak, S., Costantino, J. P., et al. (2010). Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: Results from NSABP B-14 and NSABP B-20. Journal of clinical oncology: official journal of the American Society of Clinical Oncology, 28(10), 1677–1683.
55.
Kreike, B., Halfwerk, H., Armstrong, N., Bult, P., Foekens, J. A., Veltkamp, S. C., et al. (2009). Local recurrence after breast-conserving therapy in relation to gene expression patterns in a large series of patients. Clinical cancer research: an official journal of the American Association for Cancer Research, 15(12), 4181–4190.
56.
Stephenson, A. J., Kattan, M. W., Eastham, J. A., Bianco, F. J., Jr., Yossepowitch, O., Vickers, A. J., et al. (2009). Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era. Journal of clinical oncology: official journal of the American Society of Clinical Oncology, 27(26), 4300–4305.
57.
Zelefsky, M. J., Kattan, M. W., Fearn, P., Fearon, B. L., Stasi, J. P., Shippy, A. M., et al. (2007). Pretreatment nomogram predicting ten-year biochemical outcome of three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for prostate cancer. Urology, 70(2), 283–287.PubMed
58.
Roach, M., 3rd, Waldman, F., & Pollack, A. (2009). Predictive models in external beam radiotherapy for clinically localized prostate cancer. Cancer, 115(13 Suppl), 3112–3120.PubMed
59.
Roach, M., 3rd, Bae, K., Speight, J., Wolkov, H. B., Rubin, P., Lee, R. J., et al. (2008). Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: Long-term results of RTOG 8610. Journal of clinical oncology: official journal of the American Society of Clinical Oncology, 26(4), 585–591.
60.
Horwitz, E. M., Bae, K., Hanks, G. E., Porter, A., Grignon, D. J., Brereton, H. D., et al. (2008). Ten-year follow-up of radiation therapy oncology group protocol 92-02: A phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology, 26(15), 2497–2504.
61.
Hanks, G. E., Hanlon, A. L., Pinover, W. H., Horwitz, E. M., Price, R. A., & Schultheiss, T. (2000). Dose selection for prostate cancer patients based on dose comparison and dose response studies. International journal of radiation oncology, biology, physics, 46(4), 823–832.PubMed
62.
Pollack, A., Zagars, G. K., Smith, L. G., Lee, J. J., Von Eschenbach, A. C., Antolak, J. A., et al. (2000). Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology, 18(23), 3904–3911.
63.
Kuban, D. A., Tucker, S. L., Dong, L., Starkschall, G., Huang, E. H., Cheung, M. R., et al. (2008). Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. International journal of radiation oncology, biology, physics, 70(1), 67–74.PubMed
64.
Grignon, D. J., Caplan, R., Sarkar, F. H., Lawton, C. A., Hammond, E. H., Pilepich, M. V., et al. (1997). p53 status and prognosis of locally advanced prostatic adenocarcinoma: A study based on RTOG 8610. Journal of the National Cancer Institute, 89(2), 158–165.PubMed
65.
Che, M., DeSilvio, M., Pollack, A., Grignon, D. J., Venkatesan, V. M., Hanks, G. E., et al. (2007). Prognostic value of abnormal p53 expression in locally advanced prostate cancer treated with androgen deprivation and radiotherapy: a study based on RTOG 9202. International journal of radiation oncology, biology, physics, 69(4), 1117–1123.PubMed
66.
Khor, L. Y., Moughan, J., Al-Saleem, T., Hammond, E. H., Venkatesan, V., Rosenthal, S. A., et al. (2007). Bcl-2 and Bax expression predict prostate cancer outcome in men treated with androgen deprivation and radiotherapy on radiation therapy oncology group protocol 92–02. Clinical cancer research: an official journal of the American Association for Cancer Research, 13(12), 3585–3590.
67.
Vergis, R., Corbishley, C. M., Thomas, K., Horwich, A., Huddart, R., Khoo, V., et al. (2010). Expression of Bcl-2, p53, and MDM2 in localized prostate cancer with respect to the outcome of radical radiotherapy dose escalation. International journal of radiation oncology, biology, Physics, 78(1), 35–41.PubMed
68.
Khor, L.-Y., Bae, K., Paulus, R., Al-Saleem, T., Hammond, M. E., Grignon, D. J., et al. (2009). MDM2 and Ki-67 predict for distant metastasis and mortality in men treated with radiotherapy and androgen deprivation for prostate cancer: RTOG 92–02. Journal of clinical oncology: official journal of the American Society of Clinical Oncology, 27(19), 3177–3184.
69.
Zhang, M., Ho, A., Hammond, E. H., Suzuki, Y., Bermudez, R. S., Lee, R. J., et al. (2009). Prognostic value of survivin in locally advanced prostate cancer: Study based on RTOG 8610. International journal of radiation oncology, biology, physics, 73(4), 1033–1042.PubMed
70.
Chakravarti, A., Heydon, K., Wu, C. L., Hammond, E., Pollack, A., Roach, M., et al. (2003). Loss of p16 expression is of prognostic significance in locally advanced prostate cancer: An analysis from the Radiation Therapy Oncology Group protocol 86–10. Journal of clinical oncology: official journal of the American Society of Clinical Oncology, 21(17), 3328–3334.
71.
Chakravarti, A., DeSilvio, M., Zhang, M., Grignon, D., Rosenthal, S., Asbell, S. O., et al. (2007). Prognostic value of p16 in locally advanced prostate cancer: a study based on Radiation Therapy Oncology Group Protocol 9202. Journal of clinical oncology: official journal of the American Society of Clinical Oncology, 25(21), 3082–3089.
72.
Li, R., Heydon, K., Hammond, M. E., Grignon, D. J., Roach, M., 3rd, Wolkov, H. B., et al. (2004). Ki-67 staining index predicts distant metastasis and survival in locally advanced prostate cancer treated with radiotherapy: An analysis of patients in radiation therapy oncology group protocol 86–10. Clinical cancer research: an official journal of the American Association for Cancer Research, 10(12 Pt 1), 4118–4124.
73.
Pollack, A., DeSilvio, M., Khor, L.-Y., Li, R., Al-Saleem, T. I., Hammond, M. E., et al. (2004). Ki-67 staining is a strong predictor of distant metastasis and mortality for men with prostate cancer treated with radiotherapy plus androgen deprivation: Radiation Therapy Oncology Group Trial 92–02. Journal of clinical oncology: official journal of the American Society of Clinical Oncology, 22(11), 2133–2140.
74.
Khor, L.-Y., Bae, K., Pollack, A., Hammond, M. E. H., Grignon, D. J., Venkatesan, V. M., et al. (2007). COX-2 expression predicts prostate-cancer outcome: Analysis of data from the RTOG 92–02 trial. The Lancet Oncology, 8(10), 912–920.PubMed
75.
Khor, L.-Y., Bae, K., Al-Saleem, T., Hammond, E. H., Grignon, D. J., Sause, W. T., et al. (2008). Protein kinase A RI-alpha predicts for prostate cancer outcome: analysis of radiation therapy oncology group trial 86–10. International Journal of radiation oncology, biology, physics, 71(5), 1309–1315.PubMed
76.
Pollack, A., Bae, K., Khor, L.-Y., Al-Saleem, T., Hammond, M. E., Venkatesan, V., et al. (2009). The importance of protein kinase A in prostate cancer: relationship to patient outcome in Radiation Therapy Oncology Group trial 92–02. Clinical cancer research: an official journal of the American Association for Cancer Research, 15(17), 5478–5484.
77.
Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: Individual patient data meta-analysis. (2010). Cochrane database of systematic reviews (Online), (1), CD008285.
78.
Bachtiary, B., Schindl, M., Pötter, R., Dreier, B., Knocke, T. H., Hainfellner, J. A., et al. (2003). Overexpression of hypoxia-inducible factor 1alpha indicates diminished response to radiotherapy and unfavorable prognosis in patients receiving radical radiotherapy for cervical cancer. Clinical cancer research: an official journal of the American Association for Cancer Research, 9(6), 2234–2240.
79.
Burri, P., Djonov, V., Aebersold, D. M., Lindel, K., Studer, U., Altermatt, H. J., et al. (2003). Significant correlation of hypoxia-inducible factor-1alpha with treatment outcome in cervical cancer treated with radical radiotherapy. International journal of radiation oncology, biology, physics, 56(2), 494–501.PubMed
80.
Rischin, D., Narayan, K., Oza, A. M., Mileshkin, L., Bernshaw, D., Choi, J., et al. (2010). Phase 1 study of tirapazamine in combination with radiation and weekly cisplatin in patients with locally advanced cervical cancer. International journal of gynecological cancer: official journal of the International Gynecological Cancer Society, 20(5), 827–833.
81.
Harima, Y., Sawada, S., Nagata, K., Sougawa, M., & Ohnishi, T. (2002). Human papilloma virus (HPV) DNA associated with prognosis of cervical cancer after radiotherapy. International journal of radiation oncology, biology, physics, 52(5), 1345–1351.PubMed
82.
Bachtiary, B., Obermair, A., Dreier, B., Birner, P., Breitenecker, G., Knocke, T.-H., et al. (2002). Impact of multiple HPV infection on response to treatment and survival in patients receiving radical radiotherapy for cervical cancer. International journal of cancer. Journal international du cancer, 102(3), 237–243.PubMed
83.
Ishikawa, H., Mitsuhashi, N., Sakurai, H., Maebayashi, K., & Niibe, H. (2001). The effects of p53 status and human papillomavirus infection on the clinical outcome of patients with stage IIIB cervical carcinoma treated with radiation therapy alone. Cancer, 91(1), 80–89.PubMed
84.
Kim, J.-Y., Park, S., Nam, B.-H., Roh, J.-W., Lee, C. H., Kim, Y.-H., et al. (2009). Low initial human papilloma viral load implicates worse prognosis in patients with uterine cervical cancer treated with radiotherapy. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 27(30), 5088–5093.
85.
Loncaster, J. A., Cooper, R. A., Logue, J. P., Davidson, S. E., Hunter, R. D., & West, C. M. (2000). Vascular endothelial growth factor (VEGF) expression is a prognostic factor for radiotherapy outcome in advanced carcinoma of the cervix. British Journal of Cancer, 83(5), 620–625.PubMed
86.
Noordhuis, M. G., Eijsink, J. J. H., Ten Hoor, K. A., Roossink, F., Hollema, H., Arts, H. J. G., et al. (2009). Expression of epidermal growth factor receptor (EGFR) and activated EGFR predict poor response to (chemo)radiation and survival in cervical cancer. Clinical cancer research: an official journal of the American Association for Cancer Research, 15(23), 7389–7397.
87.
Kim, G. E., Kim, Y. B., Cho, N. H., Chung, H.-C., Pyo, H. R., Lee, J. D., et al. (2004). Synchronous coexpression of epidermal growth factor receptor and cyclooxygenase-2 in carcinomas of the uterine cervix: A potential predictor of poor survival. Clinical cancer research: an official journal of the American Association for Cancer Research, 10(4), 1366–1374.
88.
Wong, Y. F., Selvanayagam, Z. E., Wei, N., Porter, J., Vittal, R., Hu, R., et al. (2003). Expression genomics of cervical cancer: molecular classification and prediction of radiotherapy response by DNA microarray. Clinical cancer research: an official journal of the American Association for Cancer Research, 9(15), 5486–5492.
89.
Weidhaas, J. B., Li, S.-X., Winter, K., Ryu, J., Jhingran, A., Miller, B., et al. (2009). Changes in gene expression predicting local control in cervical cancer: results from Radiation Therapy Oncology Group 0128. Clinical cancer research: an official journal of the American Association for Cancer Research, 15(12), 4199–4206.
90.
Heald, R. J., & Ryall, R. D. (1986). Recurrence and survival after total mesorectal excision for rectal cancer. Lancet, 1(8496), 1479–1482.PubMed
91.
Van Gijn, W., Marijnen, C. A. M., Nagtegaal, I. D., Kranenbarg, E. M.-K., Putter, H., Wiggers, T., et al. (2011). Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. The Lancet Oncology, 12(6), 575–582.PubMed
92.
Braendengen, M., Tveit, K. M., Berglund, A., Birkemeyer, E., Frykholm, G., Påhlman, L., et al. (2008). Randomized phase III study comparing preoperative radiotherapy with chemoradiotherapy in nonresectable rectal cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology, 26(22), 3687–3694.
93.
Giralt, J., De las Heras, M., Cerezo, L., Eraso, A., Hermosilla, E., Velez, D., et al. (2005). The expression of epidermal growth factor receptor results in a worse prognosis for patients with rectal cancer treated with preoperative radiotherapy: A multicenter, retrospective analysis. Radiotherapy and oncology: journal of the European Society for Therapeutic Radiology and Oncology, 74(2), 101–108.
94.
Kim, J.-S., Kim, J.-M., Li, S., Yoon, W.-H., Song, K.-S., Kim, K.-H., et al. (2006). Epidermal growth factor receptor as a predictor of tumor downstaging in locally advanced rectal cancer patients treated with preoperative chemoradiotherapy. International journal of radiation oncology, biology, physics, 66(1), 195–200.PubMed
95.
Spindler, K.-L. G., Nielsen, J. N., Lindebjerg, J., Brandslund, I., & Jakobsen, A. (2006). Prediction of response to chemoradiation in rectal cancer by a gene polymorphism in the epidermal growth factor receptor promoter region. International journal of radiation oncology, biology, physics, 66(2), 500–504.PubMed
96.
Machiels, J.-P., Sempoux, C., Scalliet, P., Coche, J.-C., Humblet, Y., Van Cutsem, E., et al. (2007). Phase I/II study of preoperative cetuximab, capecitabine, and external beam radiotherapy in patients with rectal cancer. Annals of oncology: official journal of the European Society for Medical Oncology / ESMO, 18(4), 738–744.
97.
Bengala, C., Bettelli, S., Bertolini, F., Salvi, S., Chiara, S., Sonaglio, C., et al. (2009). Epidermal growth factor receptor gene copy number, K-ras mutation and pathological response to preoperative cetuximab, 5-FU and radiation therapy in locally advanced rectal cancer. Annals of oncology: official journal of the European Society for Medical Oncology / ESMO, 20(3), 469–474.
98.
Erben, P., Ströbel, P., Horisberger, K., Popa, J., Bohn, B., Hanfstein, B., et al. (2011). KRAS and BRAF mutations and PTEN expression do not predict efficacy of cetuximab-based chemoradiotherapy in locally advanced rectal cancer. International journal of radiation oncology, biology, physics, 81(4), 1032–1038.PubMed
99.
He, Y., Van’t Veer, L. J., Mikolajewska-Hanclich, I., Van Velthuysen, M.-L. F., Zeestraten, E. C. M., Nagtegaal, I. D., et al. (2009). PIK3CA mutations predict local recurrences in rectal cancer patients. Clinical cancer research: an official journal of the American Association for Cancer Research, 15(22), 6956–6962.
100.
Saw, R. P. M., Morgan, M., Koorey, D., Painter, D., Findlay, M., Stevens, G., et al. (2003). p53, deleted in colorectal cancer gene, and thymidylate synthase as predictors of histopathologic response and survival in low, locally advanced rectal cancer treated with preoperative adjuvant therapy. Diseases of the colon and rectum, 46(2), 192–202.PubMed
101.
Negri, F. V., Campanini, N., Camisa, R., Pucci, F., Bui, S., Ceccon, G., et al. (2008). Biological predictive factors in rectal cancer treated with preoperative radiotherapy or radiochemotherapy. British Journal of Cancer, 98(1), 143–147.PubMed
102.
Terrazzino, S., Agostini, M., Pucciarelli, S., Pasetto, L. M., Friso, M. L., Ambrosi, A., et al. (2006). A haplotype of the methylenetetrahydrofolate reductase gene predicts poor tumor response in rectal cancer patients receiving preoperative chemoradiation. Pharmacogenetics and Genomics, 16(11), 817–824.PubMed
103.
Ghadimi, B. M., Grade, M., Difilippantonio, M. J., Varma, S., Simon, R., Montagna, C., et al. (2005). Effectiveness of gene expression profiling for response prediction of rectal adenocarcinomas to preoperative chemoradiotherapy. Journal of clinical oncology: official journal of the American Society of Clinical Oncology, 23(9), 1826–1838.
104.
Watanabe, T., Komuro, Y., Kiyomatsu, T., Kanazawa, T., Kazama, Y., Tanaka, J., et al. (2006). Prediction of sensitivity of rectal cancer cells in response to preoperative radiotherapy by DNA microarray analysis of gene expression profiles. Cancer Research, 66(7), 3370–3374.PubMed
105.
Garcia-Aguilar, J., Chen, Z., Smith, D. D., Li, W., Madoff, R. D., Cataldo, P., et al. (2011). Identification of a biomarker profile associated with resistance to neoadjuvant chemoradiation therapy in rectal cancer. Annals of Surgery, 254(3), 486–492. discussion 492–493.PubMed
106.
Chargari, C., Soria, J.-C., & Deutsch, E. (2013). Controversies and challenges regarding the impact of radiation therapy on survival. Annals of oncology: official journal of the European Society for Medical Oncology/ESMO, 24(1), 38–46.
Metadata
Title
Personalized radiation therapy and biomarker-driven treatment strategies: a systematic review
Authors
Jean-Emmanuel Bibault
Ingrid Fumagalli
Charles Ferté
Cyrus Chargari
Jean-Charles Soria
Eric Deutsch
Publication date
01-12-2013
Publisher
Springer US
Published in
Cancer and Metastasis Reviews / Issue 3-4/2013
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI
https://doi.org/10.1007/s10555-013-9419-7

Other articles of this Issue 3-4/2013

Cancer and Metastasis Reviews 3-4/2013 Go to the issue

OriginalPaper

Systems biology of cancer: entropy, disorder, and selection-driven evolution to independence, invasion and “swarm intelligence”

OriginalPaper

Aneuploidy and chromosomal instability: a vicious cycle driving cellular evolution and cancer genome chaos

CLINICAL

Adverse reactions to targeted and non-targeted chemotherapeutic drugs with emphasis on hypersensitivity responses and the invasive metastatic switch

OriginalPaper

Chromosomal instability (CIN): what it is and why it is crucial to cancer evolution

NON-THEMATIC REVIEW

Role of the host stroma in cancer and its therapeutic significance

OriginalPaper

Do mutator mutations fuel tumorigenesis?
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits